

May 1, 2019



# SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)

## Presentations to be available on Monday May 6, 2019

JERSEY CITY, N.J., May 1, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that data further demonstrating the potential for ibrexafungerp to treat VVC will be presented in one oral and two ePoster presentations at the 2019 American College of Obstetrics and Gynecology Annual Clinical and Scientific Meeting (ACOG), May 3-6, 2019 in Nashville, Tennessee.

Ibrexafungerp, the first representative of a novel family of compounds referred to as "fungerp" (antifungal triterpenoids), is being developed for oral and intravenous administration and is in clinical development for the treatment of several serious fungal infections, including VVC, invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections, including *Candida auris*. Ibrexafungerp is currently in Phase 3 development in VVC.

ACOG, as one of the premier U.S. obstetrics and gynecology clinical and scientific meetings, brings together experts to present their latest findings, guidelines and experiences. Titles and timing of the three ibrexafungerp presentations are as follows:

### ***Oral Presentation***

**Title:** *In Vitro* Activity of Ibrexafungerp (SCY-078) Against *Candida* spp. (including Fluconazole-resistant Isolates)

**Presenter:** Stephen Barat, PhD

**Date and Time:** Friday, May 3, 10:30 AM CDT

**Oral Presentation #:** 140P

**Session:** Oral Presentation M

### ***ePoster Presentations***

**Title:** A Phase 2b, Dose-Finding Study Evaluating Oral Ibrexafungerp vs Fluconazole in Vulvovaginal Candidiasis (DOVE)

**Presenter:** David Angulo, MD

**Date and Time:** Saturday, May 4, 11:30 AM CDT

**Poster Presentation #:** 24J

**Session:** ePoster Session J

**Title:** Ibrexafungerp, a Novel Oral Antifungal, Demonstrates No Reproductive or Developmental Harm in Preclinical Models

**Presenter:** Christina Carruthers, PhD

**Date and Time:** Saturday, May 4, 11:30 AM CDT

**Poster Presentation #:** 25J

**Session:** ePoster Session J

The ACOG 2019 presentations will be available on the [SCYNEXIS website](#) following the event.

### **About SCYNEXIS**

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The [SCYNEXIS team](#) has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by *Candida*, *Aspergillus* and *Pneumocystis* species. For more information, visit [www.scynexis.com](http://www.scynexis.com).

### **Forward Looking Statement**

Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in SCYNEXIS's ability to successfully develop and obtain FDA approval for ibrexafungerp. These and other risks are described more fully in SCYNEXIS's filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K under the caption "Risk Factors" and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

### **CONTACT:**

#### **Investor Relations**

Heather Savelle

Argot Partners

Tel: 212-600-1902

[heather@argotpartners.com](mailto:heather@argotpartners.com)

#### **Media Relations**

George E. MacDougall

MacDougall

Tel: 781-235-3093

[george@macbiocom.com](mailto:george@macbiocom.com)

[at-acog-2019-further-demonstrating-the-favorable-profile-of-ibrexafungerp-for-the-treatment-of-vulvovaginal-candidiasis-vvc-300841608.html](https://www.acog.org/clinical/clinical-guidance/abstract/2019/04/ibrexafungerp-for-the-treatment-of-vulvovaginal-candidiasis-vvc-300841608.html)

SOURCE SCYNEXIS, Inc.